Vaughan Nelson Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vaughan Nelson Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-482,572	Closed	-$170M	–	245
2023 Q2	$170M	Buy	482,572 +7,122	+1%	+$2.4M	1.88%	13
2023 Q1	$150M	Sell	475,450 -2,688	-0.6%	-$806K	1.85%	14
2022 Q4	$138M	Sell	478,138 -26,123	-5%	-$7.96M	1.79%	15
2022 Q3	$146M	Sell	504,261 -357,332	-41%	-$103M	2.11%	14
2022 Q2	$243M	Sell	861,593 -7,024	-0.8%	-$1.88M	3.28%	1
2022 Q1	$227M	Sell	868,617 -55,130	-6%	-$13.1M	2.57%	6
2021 Q4	$203M	Buy	+923,747	New	+$180M	2.08%	14

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vaughan Nelson Investment Management's VRTX Position: Q3 2023 in Review

Vaughan Nelson Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 482,572 shares — an estimated $170M sold.

Vaughan Nelson Investment Management first reported a position in VRTX in Q4 2021 and held it in 7 quarters. The position peaked at $243M in Q2 2022. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Vaughan Nelson Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Vaughan Nelson Investment Management sold 482,572 Vertex Pharmaceuticals shares in Q3 2023, an estimated $170M.
Vaughan Nelson Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Vaughan Nelson Investment Management's Vertex Pharmaceuticals position peaked at $243M in Q2 2022.
1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Vaughan Nelson Investment Management's 13F filing for Q3 2023, filed 9 Nov 2023.